Elevated levels of IL-6 and CRP predict the need for mechanical ventilation in COVID-19.

"Disclosure of potential conflict of interest: B. Lipworth reports grants and personal fees from Sanofi, AstraZeneca, and Teva; personal fees from Cipla, Glenmark, and Lupin; and research grants, consulting, advisory board, personal fees from Chiesi, outside the submitted work; in addition, he reports that his son is an employee of AstraZeneca. M. von Bergwelt-Baildon is the local principal investigator of the COVACTA-Trial (A Study to Evaluate the Safety and Efficacy of Tocilizumab in Patients with Severe COVID-19 Pneumonia [NCT04320615]; sponsored by Hoffmann-La Roche), which is currently being conducted, and he has previously received honoraria and research funding from Hoffman-La Roche unrelated to this project. M. Klein has received speaker fees from BioMerieux and served on the advisory board of BioMerieux. The rest of the authors declare that they have no relevant conflicts of interest."

"Disclosure of potential conflict of interest: B. Lipworth reports grants and personal fees from Sanofi, AstraZeneca, and Teva; personal fees from Cipla, Glenmark, and Lupin; and research grants, consulting, advisory board, personal fees from Chiesi, outside the submitted work; in addition, he reports that his son is an employee of AstraZeneca. M. von Bergwelt-Baildon is the local principal investigator of the COVACTA-Trial (A Study to Evaluate the Safety and Efficacy of Tocilizumab in Patients with Severe COVID-19 Pneumonia [NCT04320615]; sponsored by Hoffmann-La Roche), which is currently being conducted, and he has previously received honoraria and research funding from Hoffman-La Roche unrelated to this project. M. Klein has received speaker fees from BioMerieux and served on the advisory board of BioMerieux. The rest of the authors declare that they have no relevant conflicts of interest."